市場調査レポート

商品コード

1434672

血管浮腫治療薬市場：薬剤タイプ、投与経路、エンドユーザー別-2024-2030年の世界予測

Angioedema Treatment Market by Drugs Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Injections, Oral), End-User - Global Forecast 2024-2030

出版日: 2024年01月15日 | 発行: 360iResearch

| ページ情報: 英文 183 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 744,453円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 901,213円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,057,973円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,371,493円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

血管浮腫治療薬市場規模は2023年に46億9,000万米ドルと推計され、2024年には55億米ドルに達し、CAGR 17.28%で2030年には143億2,000万米ドルに達すると予測されます。

血管浮腫治療薬の世界市場

主な市場の統計
基準年[2023］	46億9,000万米ドル
予測年[2024］	55億米ドル
予測年 [2030]	143億2,000万米ドル
CAGR（%）	17.28%

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは血管浮腫治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、血管浮腫治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-血管浮腫治療薬市場の市場規模および予測は？

2-血管浮腫治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-血管浮腫治療薬市場における技術動向と規制の枠組みは？

4-血管浮腫治療薬市場における主要ベンダーの市場シェアは？

5-血管浮腫治療薬市場への参入に適した形態や戦略的手段は？

市場力学
- 促進要因
  - 遺伝性血管浮腫（HAE）の症例が増加
  - 国民の意識レベルを向上させる取り組みの拡大
  - 病気に関連した遺伝子変異の発生率の上昇
- 抑制要因
  - 血管浮腫の誤診
- 機会
  - より迅速な診断を促進し、最適な標準治療を提供するための政府の取り組み
  - 遺伝性血管浮腫障害治療のための先進的治療法の開発
- 課題
  - 治療に使用される薬の費用が高額になる
市場セグメンテーション分析
市場動向分析
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み

第6章血管浮腫治療薬市場薬の種類別

C1エステラーゼ阻害剤
- ベリナート
- シンライズ
- ハエガルダ
- ルコネスト
カリクレイン阻害剤
- カルビトル
選択的ブラジキニンB2受容体拮抗薬
- フィラズィル

第7章血管浮腫治療薬市場：投与経路別

注射
オーラル

第8章血管浮腫治療薬市場：エンドユーザー別

クリニック
病院
調査機関

第9章南北アメリカの血管浮腫治療薬市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第10章アジア太平洋地域の血管浮腫治療薬市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第11章欧州・中東・アフリカの血管浮腫治療薬市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第12章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ主要企業別の分析

第13章競争力のあるポートフォリオ

主要な企業プロファイル
- Adverum Biotechnologies, Inc.
- AMBOSS GmbH
- Apotex Corp.
- Attune Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc.
- Cipla USA Inc.
- CSL Behring GmbH
- Fresenius Kabi USA, LLC
- Ionis Pharmaceuticals, Inc.
- KalVista Pharmaceuticals, Inc.
- Lecturio GmbH
- Merck & Co., Inc.
- Pharming Group N.V.
- Sanofi-Aventis Groupe S.A.
- Slayback Pharma LLC
- Takeda Pharmaceutical Company Limited
- Viropharma Biologics LLC
主要な製品ポートフォリオ

第14章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. ANGIOEDEMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. ANGIOEDEMA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANGIOEDEMA TREATMENT MARKET DYNAMICS
FIGURE 7. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2030 (%)
FIGURE 8. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

TABLE 1. ANGIOEDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 6. ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 8. ANGIOEDEMA TREATMENT MARKET SIZE, BY BERINERT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANGIOEDEMA TREATMENT MARKET SIZE, BY CINRYZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANGIOEDEMA TREATMENT MARKET SIZE, BY HAEGARDA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANGIOEDEMA TREATMENT MARKET SIZE, BY RUCONEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 14. ANGIOEDEMA TREATMENT MARKET SIZE, BY KALBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 17. ANGIOEDEMA TREATMENT MARKET SIZE, BY FIRAZYR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. ANGIOEDEMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. ANGIOEDEMA TREATMENT MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 45. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 77. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 78. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 79. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 80. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 83. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 84. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 85. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 86. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 95. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 96. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 97. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 98. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 101. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 107. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 108. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 113. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 114. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 119. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 120. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 125. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 126. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 131. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 132. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 133. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 134. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. THAILAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 137. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 138. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 149. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 151. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 152. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 153. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. DENMARK ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 156. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 157. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 158. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 159. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. EGYPT ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 162. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 163. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 164. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 165. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. FINLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 168. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 169. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 170. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 174. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 175. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 186. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 187. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 188. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 189. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 197. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 198. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 199. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 204. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 205. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 206. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 207. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. NORWAY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 210. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 211. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 212. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 213. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. POLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 216. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 217. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 218. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 219. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. QATAR ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 240. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 241. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 242. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 243. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 258. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 259. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 260. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 270. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 ESTERASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONIST, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 275. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 276. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 277. ANGIOEDEMA TREATMENT MARKET LICENSE & PRICING

Product Code: MRR-436901066227

[183 Pages Report] The Angioedema Treatment Market size was estimated at USD 4.69 billion in 2023 and expected to reach USD 5.50 billion in 2024, at a CAGR 17.28% to reach USD 14.32 billion by 2030.

Global Angioedema Treatment Market

KEY MARKET STATISTICS
Base Year [2023]	USD 4.69 billion
Estimated Year [2024]	USD 5.50 billion
Forecast Year [2030]	USD 14.32 billion
CAGR (%)	17.28%

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Angioedema Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Angioedema Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Angioedema Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., AMBOSS GmbH, Apotex Corp., Attune Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., Cipla USA Inc., CSL Behring GmbH, Fresenius Kabi USA, LLC, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Lecturio GmbH, Merck & Co., Inc., Pharming Group N.V., Sanofi-Aventis Groupe S.A., Slayback Pharma LLC, Takeda Pharmaceutical Company Limited, and Viropharma Biologics LLC.

Market Segmentation & Coverage

This research report categorizes the Angioedema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drugs Type
- C1 Esterase Inhibitor
  - Berinert
  - Cinryze
  - Haegarda
  - Ruconest
- Kallikrein Inhibitor
  - Kalbitor
- Selective Bradykinin B2 Receptor Antagonist
  - Firazyr
Route of Administration
- Injections
- Oral
End-User
- Clinics
- Hospitals
- Research Organizations
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Angioedema Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Angioedema Treatment Market?

3. What are the technology trends and regulatory frameworks in the Angioedema Treatment Market?

4. What is the market share of the leading vendors in the Angioedema Treatment Market?

5. Which modes and strategic moves are suitable for entering the Angioedema Treatment Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Angioedema Treatment Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing cases of hereditary angioedema (HAE)
  - 5.1.1.2. Growing initiatives for improving awareness levels among the population
  - 5.1.1.3. Rising incidence of disease-related genetic mutations
- 5.1.2. Restraints
  - 5.1.2.1. Misdiagnosis of angioedema
- 5.1.3. Opportunities
  - 5.1.3.1. Government initiatives to facilitate faster diagnosis and provide optimal standards of treatment
  - 5.1.3.2. Development of advance therapeutics for hereditary angioedema disorders treatment
- 5.1.4. Challenges
  - 5.1.4.1. High cost of the drugs used for treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Angioedema Treatment Market, by Drugs Type

6.1. Introduction
6.2. C1 Esterase Inhibitor
- 6.3.1. Berinert
- 6.3.2. Cinryze
- 6.3.3. Haegarda
- 6.3.4. Ruconest
6.3. Kallikrein Inhibitor
- 6.4.1. Kalbitor
6.4. Selective Bradykinin B2 Receptor Antagonist
- 6.5.1. Firazyr

7. Angioedema Treatment Market, by Route of Administration

7.1. Introduction
7.2. Injections
7.3. Oral

8. Angioedema Treatment Market, by End-User

8.1. Introduction
8.2. Clinics
8.3. Hospitals
8.4. Research Organizations

9. Americas Angioedema Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Angioedema Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Angioedema Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Adverum Biotechnologies, Inc.
- 13.1.2. AMBOSS GmbH
- 13.1.3. Apotex Corp.
- 13.1.4. Attune Pharmaceuticals, Inc.
- 13.1.5. BioCryst Pharmaceuticals, Inc.
- 13.1.6. Cipla USA Inc.
- 13.1.7. CSL Behring GmbH
- 13.1.8. Fresenius Kabi USA, LLC
- 13.1.9. Ionis Pharmaceuticals, Inc.
- 13.1.10. KalVista Pharmaceuticals, Inc.
- 13.1.11. Lecturio GmbH
- 13.1.12. Merck & Co., Inc.
- 13.1.13. Pharming Group N.V.
- 13.1.14. Sanofi-Aventis Groupe S.A.
- 13.1.15. Slayback Pharma LLC
- 13.1.16. Takeda Pharmaceutical Company Limited
- 13.1.17. Viropharma Biologics LLC
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

血管浮腫治療薬市場：薬剤タイプ、投与経路、エンドユーザー別-2024-2030年の世界予測

Angioedema Treatment Market by Drugs Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Injections, Oral), End-User - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章血管浮腫治療薬市場薬の種類別

第7章血管浮腫治療薬市場：投与経路別

第8章血管浮腫治療薬市場：エンドユーザー別

第9章南北アメリカの血管浮腫治療薬市場

第10章アジア太平洋地域の血管浮腫治療薬市場

第11章欧州・中東・アフリカの血管浮腫治療薬市場

第12章競合情勢

第13章競争力のあるポートフォリオ

第14章付録

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Angioedema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Angioedema Treatment Market, by Drugs Type

7. Angioedema Treatment Market, by Route of Administration

8. Angioedema Treatment Market, by End-User

9. Americas Angioedema Treatment Market

10. Asia-Pacific Angioedema Treatment Market

11. Europe, Middle East & Africa Angioedema Treatment Market

12. Competitive Landscape

13. Competitive Portfolio

14. Appendix

血管浮腫治療薬市場：薬剤タイプ、投与経路、エンドユーザー別-2024-2030年の世界予測

Angioedema Treatment Market by Drugs Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Injections, Oral), End-User - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 血管浮腫治療薬市場薬の種類別

第7章 血管浮腫治療薬市場：投与経路別

第8章 血管浮腫治療薬市場：エンドユーザー別

第9章 南北アメリカの血管浮腫治療薬市場

第10章 アジア太平洋地域の血管浮腫治療薬市場

第11章 欧州・中東・アフリカの血管浮腫治療薬市場

第12章 競合情勢

第13章 競争力のあるポートフォリオ

第14章 付録

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Angioedema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Angioedema Treatment Market, by Drugs Type

7. Angioedema Treatment Market, by Route of Administration

8. Angioedema Treatment Market, by End-User

9. Americas Angioedema Treatment Market

10. Asia-Pacific Angioedema Treatment Market

11. Europe, Middle East & Africa Angioedema Treatment Market

12. Competitive Landscape

13. Competitive Portfolio

14. Appendix

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章血管浮腫治療薬市場薬の種類別

第7章血管浮腫治療薬市場：投与経路別

第8章血管浮腫治療薬市場：エンドユーザー別

第9章南北アメリカの血管浮腫治療薬市場

第10章アジア太平洋地域の血管浮腫治療薬市場

第11章欧州・中東・アフリカの血管浮腫治療薬市場

第12章競合情勢

第13章競争力のあるポートフォリオ

第14章付録